Hank Mansbach
2022
In 2022, Hank Mansbach earned a total compensation of $1.5M as Chief Medical Officer at 89bio, a 22% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $220,900 |
|---|---|
| Option Awards | $234,080 |
| Salary | $465,000 |
| Stock Awards | $609,360 |
| Other | $5,971 |
| Total | $1,535,311 |
Mansbach received $609.4K in stock awards, accounting for 40% of the total pay in 2022.
Mansbach also received $220.9K in non-equity incentive plan, $234.1K in option awards, $465K in salary and $6K in other compensation.
Rankings
In 2022, Hank Mansbach's compensation ranked 2,181st out of 5,760 executives tracked by ExecPay. In other words, Mansbach earned more than 62.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,181 out of 5,760 | 62nd |
Division Manufacturing | 1,174 out of 3,136 | 63rd |
Major group Chemicals And Allied Products | 505 out of 1,422 | 65th |
Industry group Drugs | 465 out of 1,323 | 65th |
Industry Pharmaceutical Preparations | 339 out of 969 | 65th |
Source: SEC filing on April 24, 2023.
Mansbach's colleagues
We found two more compensation records of executives who worked with Hank Mansbach at 89bio in 2022.
News
89bio CEO Rohan Palekar's 2023 pay jumps 79% to $5.6M
April 17, 2024
89bio CEO Rohan Palekar's 2022 pay falls 36% to $3.1M
April 24, 2023
89bio CEO Rohan Palekar's 2021 pay rises 1% to $4.9M
April 14, 2022
89bio CEO Rohan Palekar's 2020 pay jumps 378% to $4.9M
April 15, 2021
89bio CEO Rohan Palekar's 2019 pay jumps 44% to $1M
May 8, 2020